COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth

Andreas Renner; Katharina Marth; Karin Patocka; Marco Idzko; Wolfgang Pohl

doi:10.1183/23120541.00457-2020

COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth

ERJ Open Res. 2020 Nov 2;6(4):00457-2020. doi: 10.1183/23120541.00457-2020. eCollection 2020 Oct.

Authors

Andreas Renner¹, Katharina Marth¹, Karin Patocka¹, Marco Idzko², Wolfgang Pohl¹

Affiliations

¹ Karl Landsteiner Institute for Clinical and Experimental Pneumology, Hietzing Hospital, Vienna, Austria.
² Dept of Pulmonology, Medical University of Vienna, Vienna, Austria.

Abstract

Experience with very mild #COVID19 disease courses in two severe eosinophilic asthmatics with complete eosinophil depletion due to benralizumab treatment counters the recent theories that eosinophilia is protective in COVID-19 infections https://bit.ly/3cnEFvg.